Comparative Pharmacology
Head-to-head clinical analysis: ACEON versus RENOTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACEON versus RENOTEC.
ACEON vs RENOTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ACEON (perindopril) is an angiotensin-converting enzyme (ACE) inhibitor. It inhibits ACE, which converts angiotensin I to angiotensin II, a potent vasoconstrictor. This results in decreased vasopressor activity, reduced aldosterone secretion, and lower peripheral vascular resistance, leading to antihypertensive effects.
Renotec is a direct renin inhibitor that binds to the active site of renin, inhibiting the conversion of angiotensinogen to angiotensin I, thereby reducing angiotensin II levels and lowering blood pressure.
Initial: 4 mg orally once daily; titrate to 8-32 mg daily in 1-2 divided doses. Typical maintenance: 8-16 mg daily.
Enalapril 5-40 mg orally once or twice daily; initial dose 5 mg once daily, titrate based on response.
None Documented
None Documented
Perindoprilat: terminal half-life ~30 hours (up to 120 hours in elderly or heart failure due to prolonged terminal phase from slow dissociation from ACE binding); perindopril: ~1.5 hours.
Terminal elimination half-life is 12-15 hours; clinical context: supports once-daily dosing; half-life may be prolonged in renal impairment (creatinine clearance <30 mL/min).
Renal: approximately 30% as perindopril and 20% as perindoprilat; fecal: approximately 50% as metabolites.
Approximately 70% of the dose is excreted in urine as unchanged drug, and 20-30% via feces as metabolites; less than 5% is excreted unchanged in feces.
Category C
Category C
ACE Inhibitor
ACE Inhibitor